New Published Review Substantiates Benefits of NSK-SD® Nattokinase for Promoting Women’s Heart Health
WALNUT CREEK, CA — Vincent Hackel, president CEO of JBSL-USA, has announced that a newly published study, “Nattokinase (NSK) to Support Cardiovascular Health in Women: A Comprehensive Review,” appearing in EC Nutrition August 2026 (EC Nutrition (2026) 21.6: 01-13), finds there is strong evidence that supplementation with NSK-SD® mitigates several key cardiovascular risk factors in women.
In the review, the authors discuss cardiovascular risk factors throughout a woman’s life, such as specific phases (e.g., reproductive, peri-menopause, and post-menopause), as well as biological and clinical risk factors (e.g., inflammation, hypertension, adverse lipid profile and thrombosis/hemostatic factors), and the intersectionality of pathways promoting cardiovascular disease (CVD) in women. CVD is shaped by dynamic changes in lipid metabolism, endothelial function, inflammation, and thrombosis throughout a woman’s life.
A challenge that exists sets up the opportunity to investigate alternative, natural avenues of cardiovascular support. “Despite clear evidence that traditional risk factors such as dyslipidemia, hypertension, diabetes, and obesity confer equal or greater relative risk in women compared with men, women are less likely to receive timely diagnosis,
risk stratification, or guideline-recommended preventive therapies,” they write. “As a result, women often accumulate a greater lifetime burden of modifiable cardiovascular risk.”
The authors believe the studies show that nattokinase may be especially well suited to target key pathways implicated in women’s cardiovascular risk, including impaired fibrinolysis, endothelial dysfunction, and blood pressure dysregulation.
The majority of studies assessed in the work have used NSK-SD® nattokinase, and the authors state that “Emerging mechanistic and clinical evidence indicates that NSK-SD® supports cardiovascular health through multiple pathways, including enhanced fibrinolysis, modulation of coagulation factors, inhibition of platelet aggregation, improvements in endothelial function, reductions in blood pressure, and attenuation of inflammatory signaling. Human studies further suggest beneficial effects on lipid profiles, vascular function, and microcirculation.”
Hackel notes that this comprehensive review emphasizes the clinical value for women’s cardiovascular support through several pathways. “The evidence presented makes a compelling case for dietary supplement brands to formulate with NSK-SD®, the most-studied nattokinase with strong clinical results for women concerned about heart health.”
NSK-SD® is the world’s first nattokinase to enter the market, and the most studied nattokinase with more than 50+ published studies. Nattokinase is an enzyme that was discovered in the Japanese traditional fermented food natto. It is naturally produced during the fermentation process of soybeans by Bacillus subtilis natto. NSK-SD® is shown in studies to have many cardiovascular health benefits such as degrading blood clots directly and indirectly, decreasing hypertension, improving blood circulation, decreasing inflammation, and more.
JBSL-USA, Inc. is based in Walnut Creek, Calif. and helps to serve all countries in the Americas as well as Europe.
